In this issue of Blood, Zhou et al provide novel insights into Fc gamma type 2 receptor A (FcgRIIA)-mediated platelet activation. By identifying a negative regulator of FcgRIIA signaling, which is influenced by microRNA miR-148a, they present the first evidence of modulation of platelet function by microRNAs in vivo. They show that inhibition of miR-148a prevents thrombosis after immune complex-induced platelet stimulation in vivo. a novel approach by investigating potential negative regulators of FcgRIIA signaling that could explain the differences between individuals. They identify a critical role for platelet T-cell ubiquitin ligand-2 (TULA-2) as a negative regulator of FcgRIIA-mediated signaling in platelets. Platelets with low expression levels of TULA-2 strongly respond to immune complexes, whereas high levels of TULA-2 protect from platelet aggregation in response to immune complex binding to FcgRIIA (see figure) . TULA-2, which counteracts the phosphorylation of Syk, 3 is a key protein in the downregulation of receptor-mediated signal transduction in platelets in vitro and in vivo. Zhou et al showed that TULA-2 also regulates FcgRIIA-mediated signaling in platelets. Interestingly, Zhou et al find TULA-2 to be negatively regulated by miR-148a (see figure) , one of the 750 microRNAs found within platelets. 4 It comes as some surprise that platelets, which are devoid of genomic DNA, are equipped with and regulated by microRNAs. Despite lacking a nucleus, platelets contain messenger RNA (mRNA) splicing machinery and are able to translate mRNA into proteins. 5 However, the in vivo contribution of de novo synthesized platelet proteins is incompletely understood. It is also currently unclear whether microRNAs have any function in platelets or if they act solely on the megakaryocyte level. Several in vitro studies provided solid evidence for a role of microRNAs in megakaryocyte development and platelet production. These modulations could subsequently affect platelet activation and Regulation of FcgRIIA signaling by TULA-2 and miR-148a. Binding of immune complexes to platelet FcgRIIA receptor leads to platelet activation and subsequent thrombotic complications resulting in heparin-and immune-induced thrombocytopenia. Platelet TULA-2 negatively regulates platelet activation downstream of FcgRIIA by diminishing spleen tyrosine kinase (Syk) phosphorylation (P). Intraplatelet TULA-2 levels therefore mediate FcgRIIA-induced platelet activation and thereby determine platelet responsiveness to heparin-or immune-mediated antigen-antibody complexes. In turn, intraplatelet TULA-2 is negatively regulated by microRNA miR-148a. Treatment of mice with anti-miR-148a results in diminished thrombotic complications in vivo.
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For personal use only. on September 23, 2017. by guest www.bloodjournal.org From reactivity. Megakaryocytes equip platelets with RNA and microRNA, thereby allowing platelets to mirror the condition of their progenitors. Platelets further take up various RNAs from cells they encounter within the circulation. Platelets also transfer mRNA and microRNAs from one cell to another via release of microvesicles, which allows platelets to communicate with a variety of different cell types, thereby modulating target cell effector functions in various diseases. 6 Emerging lines of evidence indicate that platelet microRNAs are biologically and clinically relevant regulators of protein translocation and may serve as biomarkers for thrombotic disease and platelet reactivity, with possible therapeutic applications in the future. Whether the in vivo effects observed by anti-miR-148a are solely the result of FcgRIIA signaling in platelets or whether other cells are also involved remains to be determined. Recently, it was also shown that FcgRIIA signaling in monocytes contributes to thrombotic complications. Monocyte FcgRIIA signaling induces tissue factor production and subsequent thrombin generation in an Syk-dependent fashion. 7 Therefore, anti-miR-148a treatment might also have beneficial antithrombotic effects on cell types other than platelets. The study by Zhou et al brings us one step closer to understanding the underlying mechanism of inter-individual differences in response to FcgRIIA-mediated signaling in platelets. TULA-2 and miR-148a could potentially serve as predictive markers to identify patients at risk of HIT. However, the utility of anti-miR-148a as a therapeutic target is doubtful, because miR-148a has many crucial functions in other cell types. It was previously reported that miR-148a is a tumor-suppressive microRNA that potently induces apoptosis of tumor cells.
8 Therefore miR-148a itself has been suggested as a therapeutic target, which, given the effects of this microRNA on platelet activation and subsequent thrombotic complications demonstrated by Zhou et al, should be reconsidered.
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